MedPointe and Opportunities in Specialty Pharma: Speed is Expensive
Executive Summary
The notion of building up a new drug company with the unwanted, undersized products of ever-bigger Big Pharma is hardly new. But MedPointe, with its acquisition of Carter Wallace's medical products business, is aiming to build up a new firm faster and bigger than can be done simply by in-licensing.You may also be interested in...
MedPointe's Private Dilemma
MedPointe was born via the leveraged buy-out of an old, private pharmaceutical company, Carter-Wallace. Accepting financial strictures was part of the deal; the company must remain profitable. This increases the challenge for the "founders," seasoned pharma execs intent on leveraging the infrastructure they overhauled, to created an in-licensing based marketing powerhouse. Beyond competing with bigger pharma marketers, management's challenge remains bringing in new assets affordably.
MedPointe's Private Dilemma
MedPointe was born via the leveraged buy-out of an old, private pharmaceutical company, Carter-Wallace. Accepting financial strictures was part of the deal; the company must remain profitable. This increases the challenge for the "founders," seasoned pharma execs intent on leveraging the infrastructure they overhauled, to created an in-licensing based marketing powerhouse. Beyond competing with bigger pharma marketers, management's challenge remains bringing in new assets affordably.
Shire: Too Big For Its Niches
When UK specialty pharmaceutical company Shire Pharmaceuticals announced its $4 billion all-share acquisition of Canada's BioChem Pharma in December, the markets punished it with a 16% drop in share price. But Shire is getting too big to acquire merely niche product opportunities.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports